With more than 30 years’ experience in technical support and then sales in the cosmetics, toiletries and pharmaceutical packaging industries, Gannon joins Toolrite from German pharmaceutical organisation Uhlmann, where he held the role of sales manager for 10 years.
Gaining an HND in Mechanical & Production Engineering, Gannon further strengthened his technical expertise as sales engineer with Uhlmann agent, Ultrapac.
Toolrite appoints sales director
Steve Gannon takes newly formed position
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Britain's biotech potential (part II): world-class science, second-class support?
In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Finance
Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach
The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position
Manufacturing
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform
The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
Finance
UK biotech venture capital rises 17% in Q1 2026 as deal activity surges 67% year-on-year, BIA figures show
Total UK biotech equity financing reached £552m in the first quarter of 2026, driven by a 17% quarterly rise in venture capital investment, according to BioIndustry Association data, though public markets remain dormant with no IPOs recorded since 2022
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
Britain's biotech potential (part I): world-class science, second-class support?
The UK produces top-tier life sciences research, offers favourable conditions for early-stage investment and hosts a growing network of internationally competitive clusters. So why does the capital keep leaving?